Sanofi nears selling 50 percent controlling stake in Opella to CD&R
Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 percent controlling stake in Opella to CD&R, following completion of the required social and corporate procedures.
Bpifrance is expected to participate as a minority shareholder with a c.2% stake in Opella, with Sanofi remaining a significant shareholder.
The terms of the transaction remain unchanged from those previously disclosed, and closing is expected to take place in Q2 2025 at the earliest.
This transaction remains subject to obtaining customary regulatory approvals from the competent authorities.
Read also: Sanofi's Merilog Receives USFDA Approval as Biosimilar to Novolog for Diabetes Management
Most recently, the Paris-based firm has made the announcement that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP). BP is a chronic, debilitating, and relapsing skin disease with underlying type-2 inflammation that typically occurs in an elderly population. It is characterized by intense itch and blisters, reddening of the skin, and painful lesions. The blisters and rash can form over much of the body and cause the skin to bleed and crust, resulting in patients being more prone to infection and affecting their daily functioning. Approximately 27,000 adults in the US live with BP that is uncontrolled by systemic corticosteroids.
Read also: USFDA grants priority review to Sanofi-Regeneron Dupixent for bullous pemphigoid
